Mumbai, Dec. 2 -- Biocon Biologics, a subsidiary of Biocon, announced a settlement agreement with Amgen Inc. that clears the path for the commercialization of its Denosumab biosimilars in Europe and the rest of the world.
Published by HT Digital Content Services with permission from Capital Market....